The ability to overcome obviousness rejections under 35 U.S.C. 103 before the USPTO is a key skill for patent practitioners. Recent USPTO statistics show that obviousness rejections are issued in 79% of office actions with at least one rejection. How can you win key patent rights for your clients as anticipation rejections wane in popularity and frequency, and obviousness rejections rage? We will discuss obviousness at a foundational level and progress to drafting strategies and practice tips to help you overcome obviousness at the USPTO.
Loren Hulse, Partner at Holland & Hart, delivers sophisticated counsel in the creation, management, and protection of domestic and foreign patent and trademark portfolios to companies disrupting the life sciences, chemical, pharmaceutical, biotech, manufacturing, and medical device industries.
From his experience working as former in-house intellectual property counsel for NPS Pharmaceuticals and as patent counsel for Ceramatec, Inc., Loren understands the business imperative to create robust protection strategies while managing patent and trademark portfolios that align with corporate priorities.
As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA-related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.
Before joining Holland & Hart, Loren was a partner at Stoel Rives, where he served as the co-leader of the firm’s Life Sciences industry group.
Target Audience: IP practitioners with U.S. assets in their portfolio who would benefit from support in dealing with the rise of obviousness rejections at the USPTO.